WCLC 2023 | Outcomes of I-SABR in lung cancer

Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, Texas, comments on the efficacy of stereotactic ablative radiotherapy (SABR) alongside immunotherapy (I-SABR) in the treatment of lung cancer. Many patients with lung cancer develop secondary malignancies that are undetectable through circulating tumour (ct)-DNA analysis. Consequently, immunotherapy is an important second-line treatment to reduce the recurrence of cancer and treat microscopic malignancies. Prof. Chang shares that high dose I-SABR has been shown to have a dramatic effect on reducing the recurrence of lung cancer, hence immunotherapy can be effective in this clinical setting. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.